The Catalyst

Fact Check Friday: The truth about biopharmaceutical patents

Posted by Mark Grayson on August 26, 2016 at 2:59 PM

MYTH: Biopharmaceutical companies use government-protected monopolies to raise costs on medicines.

FACT: Patent-protected medicines routinely face competition from other brand name medicines, which helps drive down costs while patent protection and intellectual property rights allow the biopharmaceutical industry to develop life-saving medicines and cures.

Read More

Topics: Innovation, Patents, IP, Patent Protections

Medicare Monday: Increased rebate levels in Part D show robust negotiation continues

Posted by Nicole Longo on August 22, 2016 at 9:00 AM

A key component of the success of Part D is the negotiation and competition that occurs, helping to keep costs low for beneficiaries and taxpayers.

The way the program works is Part D purchasers negotiate discounts and rebates with prescription drug manufacturers. Because these large, powerful purchasers represent as many as 60 to 120 million covered lives, they have significant leverage to negotiate large discounts and rebates with manufactures on behalf of Part D plans. These savings are used to help reduce premiums, deductibles and cost sharing for Part D beneficiaries.

Read More

Topics: Part D, Medicare, Medicare Monday

New report highlights more than 250 vaccines in development

Posted by Hannah Mooney on August 18, 2016 at 12:00 PM

More than 200 years ago, the first vaccine was developed for smallpox, and now, the disease has been eradicated worldwide. And in the United States, the transmission of poliovirus, measles and rubella have been eliminated. These are examples of tremendous scientific progress, and through our growing understanding of how these and other diseases work at the molecular level, many new therapeutic and preventative vaccines have been developed.

Read More

Topics: Medicines in Development, Vaccines, Prevention

In biopharmaceutical research, if at first you don’t succeed, try again

Posted by Andrew Powaleny on August 17, 2016 at 2:23 PM

In case you missed it, an article in STAT News today profiles setbacks inside the process of researching new treatments and cures for patients. For America’s biopharmaceutical research companies, setbacks are far more common than success, but these stumbling blocks provide invaluable knowledge that help guide and direct researchers to get one step closer to the next scientific advancement.

Read More

Topics: Drug Development, Neurological Disease

340B Spotlight: Retail pharmacies continue to expand the 340B program

Posted by Rebecca Davison on August 17, 2016 at 9:00 AM

One area of needed reform in the 340B program is the use of contract pharmacy arrangements. A new analysis by Drug Channels  found more than one-in-four retail, mail and specialty pharmacies in the United States is a participating contract pharmacy. Walgreens remains the biggest player in the contract pharmacy space, as they have the same number of locations as Walmart, CVS, Rite Aid, Kroger and Albertsons combined

Read More

Topics: 340B, 340B Spotlight

Study finds actual cost of 14 new medicines is billions less than predicted

Posted by Holly Campbell on August 16, 2016 at 5:00 PM

In case you missed it, a forthcoming study will disprove – once again – misleading claims pharmacy benefit managers and insurers, among others, routinely make about spending on new innovative medicines.

The Partnership for Health Analytics Research (PHAR) conducted an analysis of predictions of health care costs made prior to the introduction of 14 new medicines and found they were often dramatically overestimated.

Read More

Topics: drug cost, Value-Driven Health Care

Medicare Monday: Concerns still abound about Part B proposal

Posted by Allyson Funk on August 15, 2016 at 9:00 AM

We’ve covered many of the concerns about the government’s overreaching proposal to change Medicare Part B payments and negatively impact seniors’ access to treatment. A lack of patient protections, use of one-size-fits-all treatments and mandatory changes across Medicare are just a few.

Patients, physicians and policy experts alike are continuing to raise the alarm about the proposal. Here’s a look at what some have been saying.

Read More

Topics: Access, Medicare, Medicare Monday, seniors, Part B, CMMI

Looking ahead to PDUFA VI

Posted by Sascha Haverfield on August 11, 2016 at 12:00 PM

Next Monday, PhRMA and BIO will participate alongside patient advocates and key stakeholders in the U.S. Food and Drug Administration’s (FDA) public meeting on the reauthorization of the Prescription Drug User Fee Act (PDUFA VI).

Read More

Topics: FDA, PDUFA

340B Spotlight: New report raises questions about eligibility metric for 340B hospitals

Posted by Karyn Schwartz on August 11, 2016 at 9:00 AM

A new report from the Government Accountability Office (GAO) on how hospitals qualify for certain uncompensated care payments raises questions about how a similar eligibility metric is used to determine 340B eligibility for disproportionate share (DSH) hospitals. The vast majority (81 percent) of 340B sales are through DSH hospitals.[1] These hospitals qualify for the program in part because of the DSH metric, which is based on the proportion of inpatient care provided to Medicaid and low-income Medicare patients.

Read More

Topics: 340B, hospital eligibility, DSH metric

Dr. George Scangos: Not just science for science’s sake

Posted by Andrew Powaleny on August 10, 2016 at 9:00 AM

America’s biopharmaceutical researchers are working tirelessly to develop new and innovative medicines for patients. For those diseases that have no treatment options, the opportunity to improve patients’ lives provides daily inspiration to researchers.

In a new video, George Scangos, Ph.D., chief executive officer at Biogen, says it was early in his career when he was researching treatments for children with cystic fibrosis that he fully understood the magnitude of his work.

Read More

Topics: Alzheimer's, Drug Development, Multiple Sclerosis

I'd Like Updates


Posts by Topic

see more